구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lung cancer cohort |
Overview Company | Centre Leon Berard |
Overview Modality | CGT |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Lung Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | Targetable S100-RAGE signaling |
MoA Biomarker | biomarker testing, financial coverage, toxicity, treatment discontinuation, clinical benefit, progression-fre |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | interstitial lung disease (CT‑ILD) is a serious and potentially fatal complication in lung |
Clinical Safety signal | interstitial lung disease (CT‑ILD) is a serious and potentially fatal complication in lung |
Clinical Selected reported efficacy | ORR 56.3% |
Clinical Reported ORR | 56.3% |
Clinical Reported PFS | 8.4 |
Clinical Result source | ClinicalTrials.gov NCT03308942 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT03308942 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lung cancer cohort |
Overview Company | Centre Leon Berard |
Overview Modality | CGT |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Lung Cancer |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | Targetable S100-RAGE signaling |
MoA Biomarker | biomarker testing, financial coverage, toxicity, treatment discontinuation, clinical benefit, progression-fre |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | interstitial lung disease (CT‑ILD) is a serious and potentially fatal complication in lung |
Clinical Safety signal | interstitial lung disease (CT‑ILD) is a serious and potentially fatal complication in lung |
Clinical Selected reported efficacy | ORR 56.3% |
Clinical Reported ORR | 56.3% |
Clinical Reported PFS | 8.4 |
Clinical Result source | ClinicalTrials.gov NCT03308942 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT03308942 |
추천 비교
추천 비교